Two-year Outcomes of the FAVOR III China Trial

Dr. Lei Song from Fuwai hospital, Beijing, China, and many co-authors under the supervision of Dr. Greg Stone, presented these 2-year FU data at the TCT 2022, and the results are accepted for publication in JACC.

This is the 2-year FU of the FAVOR III China trial, in which eligible patients were randomized to a QFR®-guided strategy or a standard angiography-guided strategy. Among the 3825 randomized participants, the 2-year MACE occurred in 8.5% in the QFR®-guided group and 12.5% in the angiography-guided group, a difference of 32% in favor of the QFR®-guided group. The benefits were most pronounced among patients in whom QFR® assessment altered the planned revascularization strategy.

Please see the attached report for a complete overview of this study.

If you would like to read this article: JACC 2022; Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: Two-Year Outcomes of the FAVOR III China Trial – ScienceDirect